722 related articles for article (PubMed ID: 25426834)
1. Chimpanzee Adenovirus Vector Ebola Vaccine.
Ledgerwood JE; DeZure AD; Stanley DA; Coates EE; Novik L; Enama ME; Berkowitz NM; Hu Z; Joshi G; Ploquin A; Sitar S; Gordon IJ; Plummer SA; Holman LA; Hendel CS; Yamshchikov G; Roman F; Nicosia A; Colloca S; Cortese R; Bailer RT; Schwartz RM; Roederer M; Mascola JR; Koup RA; Sullivan NJ; Graham BS;
N Engl J Med; 2017 Mar; 376(10):928-938. PubMed ID: 25426834
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Mwesigwa B; Houser KV; Hofstetter AR; Ortega-Villa AM; Naluyima P; Kiweewa F; Nakabuye I; Yamshchikov GV; Andrews C; O'Callahan M; Strom L; Schech S; Anne Eller L; Sondergaard EL; Scott PT; Amare MF; Modjarrad K; Wamala A; Tindikahwa A; Musingye E; Nanyondo J; Gaudinski MR; Gordon IJ; Holman LA; Saunders JG; Costner PJM; Mendoza FH; Happe M; Morgan P; Plummer SH; Hickman SP; Vazquez S; Murray T; Cordon J; Dulan CNM; Hunegnaw R; Basappa M; Padilla M; Gajjala SR; Swanson PA; Lin BC; Coates EE; Gall JG; McDermott AB; Koup RA; Mascola JR; Ploquin A; Sullivan NJ; Kibuuka H; Ake JA; Ledgerwood JE;
Lancet Infect Dis; 2023 Dec; 23(12):1408-1417. PubMed ID: 37544326
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
[TBL] [Abstract][Full Text] [Related]
4. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD; Sow SO; Ndiaye BP; Mbaye KD; Thiongane A; Ndour CT; Mboup S; Ake JA; Keshinro B; Akintunde GA; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Hogrefe WR; Günther S; Naficy A; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
Lancet Infect Dis; 2020 Jun; 20(6):707-718. PubMed ID: 32199491
[TBL] [Abstract][Full Text] [Related]
5. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD; Sow SO; Mbaye KD; Thiongane A; Ndiaye BP; Ndour CT; Mboup S; Keshinro B; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Gobert P; Hogrefe WR; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
Lancet Infect Dis; 2020 Jun; 20(6):719-730. PubMed ID: 32199492
[TBL] [Abstract][Full Text] [Related]
6. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
Ewer K; Rampling T; Venkatraman N; Bowyer G; Wright D; Lambe T; Imoukhuede EB; Payne R; Fehling SK; Strecker T; Biedenkopf N; Krähling V; Tully CM; Edwards NJ; Bentley EM; Samuel D; Labbé G; Jin J; Gibani M; Minhinnick A; Wilkie M; Poulton I; Lella N; Roberts R; Hartnell F; Bliss C; Sierra-Davidson K; Powlson J; Berrie E; Tedder R; Roman F; De Ryck I; Nicosia A; Sullivan NJ; Stanley DA; Mbaya OT; Ledgerwood JE; Schwartz RM; Siani L; Colloca S; Folgori A; Di Marco S; Cortese R; Wright E; Becker S; Graham BS; Koup RA; Levine MM; Volkmann A; Chaplin P; Pollard AJ; Draper SJ; Ballou WR; Lawrie A; Gilbert SC; Hill AV
N Engl J Med; 2016 Apr; 374(17):1635-46. PubMed ID: 25629663
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
9. Open-label phase I clinical trial of Ad5-EBOV in Africans in China.
Wu L; Zhang Z; Gao H; Li Y; Hou L; Yao H; Wu S; Liu J; Wang L; Zhai Y; Ou H; Lin M; Wu X; Liu J; Lang G; Xin Q; Wu G; Luo L; Liu P; Shentu J; Wu N; Sheng J; Qiu Y; Chen W; Li L
Hum Vaccin Immunother; 2017 Sep; 13(9):2078-2085. PubMed ID: 28708962
[TBL] [Abstract][Full Text] [Related]
10. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
De Santis O; Audran R; Pothin E; Warpelin-Decrausaz L; Vallotton L; Wuerzner G; Cochet C; Estoppey D; Steiner-Monard V; Lonchampt S; Thierry AC; Mayor C; Bailer RT; Mbaya OT; Zhou Y; Ploquin A; Sullivan NJ; Graham BS; Roman F; De Ryck I; Ballou WR; Kieny MP; Moorthy V; Spertini F; Genton B
Lancet Infect Dis; 2016 Mar; 16(3):311-20. PubMed ID: 26725450
[TBL] [Abstract][Full Text] [Related]
13. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.
Tapia MD; Sow SO; Lyke KE; Haidara FC; Diallo F; Doumbia M; Traore A; Coulibaly F; Kodio M; Onwuchekwa U; Sztein MB; Wahid R; Campbell JD; Kieny MP; Moorthy V; Imoukhuede EB; Rampling T; Roman F; De Ryck I; Bellamy AR; Dally L; Mbaya OT; Ploquin A; Zhou Y; Stanley DA; Bailer R; Koup RA; Roederer M; Ledgerwood J; Hill AVS; Ballou WR; Sullivan N; Graham B; Levine MM
Lancet Infect Dis; 2016 Jan; 16(1):31-42. PubMed ID: 26546548
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
Hamer MJ; Houser KV; Hofstetter AR; Ortega-Villa AM; Lee C; Preston A; Augustine B; Andrews C; Yamshchikov GV; Hickman S; Schech S; Hutter JN; Scott PT; Waterman PE; Amare MF; Kioko V; Storme C; Modjarrad K; McCauley MD; Robb ML; Gaudinski MR; Gordon IJ; Holman LA; Widge AT; Strom L; Happe M; Cox JH; Vazquez S; Stanley DA; Murray T; Dulan CNM; Hunegnaw R; Narpala SR; Swanson PA; Basappa M; Thillainathan J; Padilla M; Flach B; O'Connell S; Trofymenko O; Morgan P; Coates EE; Gall JG; McDermott AB; Koup RA; Mascola JR; Ploquin A; Sullivan NJ; Ake JA; Ledgerwood JE;
Lancet; 2023 Jan; 401(10373):294-302. PubMed ID: 36709074
[TBL] [Abstract][Full Text] [Related]
15. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
Agnandji ST; Huttner A; Zinser ME; Njuguna P; Dahlke C; Fernandes JF; Yerly S; Dayer JA; Kraehling V; Kasonta R; Adegnika AA; Altfeld M; Auderset F; Bache EB; Biedenkopf N; Borregaard S; Brosnahan JS; Burrow R; Combescure C; Desmeules J; Eickmann M; Fehling SK; Finckh A; Goncalves AR; Grobusch MP; Hooper J; Jambrecina A; Kabwende AL; Kaya G; Kimani D; Lell B; Lemaître B; Lohse AW; Massinga-Loembe M; Matthey A; Mordmüller B; Nolting A; Ogwang C; Ramharter M; Schmidt-Chanasit J; Schmiedel S; Silvera P; Stahl FR; Staines HM; Strecker T; Stubbe HC; Tsofa B; Zaki S; Fast P; Moorthy V; Kaiser L; Krishna S; Becker S; Kieny MP; Bejon P; Kremsner PG; Addo MM; Siegrist CA
N Engl J Med; 2016 Apr; 374(17):1647-60. PubMed ID: 25830326
[TBL] [Abstract][Full Text] [Related]
17. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
18. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.
Kennedy SB; Bolay F; Kieh M; Grandits G; Badio M; Ballou R; Eckes R; Feinberg M; Follmann D; Grund B; Gupta S; Hensley L; Higgs E; Janosko K; Johnson M; Kateh F; Logue J; Marchand J; Monath T; Nason M; Nyenswah T; Roman F; Stavale E; Wolfson J; Neaton JD; Lane HC;
N Engl J Med; 2017 Oct; 377(15):1438-1447. PubMed ID: 29020589
[TBL] [Abstract][Full Text] [Related]
20. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.
Regules JA; Beigel JH; Paolino KM; Voell J; Castellano AR; Hu Z; Muñoz P; Moon JE; Ruck RC; Bennett JW; Twomey PS; Gutiérrez RL; Remich SA; Hack HR; Wisniewski ML; Josleyn MD; Kwilas SA; Van Deusen N; Mbaya OT; Zhou Y; Stanley DA; Jing W; Smith KS; Shi M; Ledgerwood JE; Graham BS; Sullivan NJ; Jagodzinski LL; Peel SA; Alimonti JB; Hooper JW; Silvera PM; Martin BK; Monath TP; Ramsey WJ; Link CJ; Lane HC; Michael NL; Davey RT; Thomas SJ;
N Engl J Med; 2017 Jan; 376(4):330-341. PubMed ID: 25830322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
